|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM222685905 |
| 003 |
DE-627 |
| 005 |
20250214154433.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2012.09.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0742.xml
|
| 035 |
|
|
|a (DE-627)NLM222685905
|
| 035 |
|
|
|a (NLM)23158694
|
| 035 |
|
|
|a (PII)S1521-6616(12)00234-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Markopoulou, Anastasia
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Small molecules in the treatment of systemic lupus erythematosus
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.10.2013
|
| 500 |
|
|
|a Date Revised 18.03.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2012 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Advances in the understanding of the cellular biological events that underlie systemic lupus erythematosus (SLE) have led to the identification of key molecules and signaling pathways that are aberrantly expressed. The parallel development of small molecule drugs that inhibit or interfere with the specific perturbations identified, offers perspective for more rational, effective and less toxic therapy. In this review, we present data from preclinical and clinical studies of such emerging novel therapies with a particular focus on kinase inhibitors and other compounds that modulate signal transduction. Moreover, we highlight the use of chromatin-modifying medications, bringing attention to the central role of epigenetics in SLE pathogenesis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a HDAC inhibitors
|
| 650 |
|
4 |
|a Jak
|
| 650 |
|
4 |
|a Kinase inhibitors
|
| 650 |
|
4 |
|a Syk
|
| 650 |
|
4 |
|a Systemic lupus erythematosus
|
| 650 |
|
7 |
|a Intracellular Signaling Peptides and Proteins
|2 NLM
|
| 650 |
|
7 |
|a Phosphoinositide-3 Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Proteasome Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Protein Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Protein-Tyrosine Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a Agammaglobulinaemia Tyrosine Kinase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a Janus Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a SYK protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a Syk Kinase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a rho-Associated Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a Calcium-Calmodulin-Dependent Protein Kinase Type 4
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.17
|2 NLM
|
| 700 |
1 |
|
|a Kyttaris, Vasileios C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 148(2013), 3 vom: 16. Sept., Seite 359-68
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:148
|g year:2013
|g number:3
|g day:16
|g month:09
|g pages:359-68
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2012.09.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 148
|j 2013
|e 3
|b 16
|c 09
|h 359-68
|